Our Statement on COVID-19


Webinar | Defining the Future of Biomarker Analysis: From Discovery to High Throughput Studies


In this webinar you'll learn more about our comprehensive multiplexed tissue imaging solutions that span applications across biomarker discovery and clinical research and validation. With its high multiplexing capability, the CODEX® platform is ideally suited for biomarker discovery applications. The Phenoptics™ solutions, built upon the legacy of the Vectra® systems and Opal™ IHC kits, are the industry standard for high throughput multiplex IHC and ideally suited for translational research and clinical trials.

The CODEX® technology was originally developed in the lab of Dr. Garry Nolan at Stanford University to simultaneous analyze of over 40 protein markers in FFPE and fresh frozen tissues through a proprietary antibody barcoding method. The CODEX System includes a benchtop fluidics instrument that integrates with standard fluorescence microscopes and turns them into high dimensional imaging systems. Our first speaker, Dr. Julia Kennedy-Darling, Director of Research and Development, describes the CODEX solution and the validation process for CODEX antibodies. She also highlights some case examples of how highly multiplexed imaging can be used for advanced cellular phenotyping.

The proven multispectral imaging (MSI) technology of the Phenoptics™ systems offers a streamlined workflow to integrate digital pathology capabilities with quantitative immunofluorescence analysis. Clifford Hoyt, VP of Translational and Clinical Programs, demonstrates the latest developments included in the Phenoptics 2.0 workflow, namely MOTiF™, which enables whole slide scanning at 20X faster scanning speeds. With a throughput of up to 80 to 200 slides per run and high sensitivity, the platform is ideal for translational and clinical research studies.